BioDelivery Story

<div class='circular--portrait' style='background:#FF0F00;color: #FFFFF0;font-size:4em;'>BS</div>
BDSI -- USA Stock  

USD 3.77  0.07  1.82%

As many investors are getting excited about healthcare space, it is fair to concentrate on BioDelivery Sciences Internatio. We will try to explain if it is still possible for BioDelivery Sciences to generate above-average margins. Is the entity valuation sustainable? Here I will cover a perspective on valuation of BioDelivery to give you a better outlook on taking a position in this stock.
Published over a month ago
View all stories for BioDelivery Sciences | View All Stories
Is BioDelivery Sciences growth trend slowing down?
This firm currently holds 79.05 M in liabilities with Debt to Equity (D/E) ratio of 0.93, which is about average as compared to similar companies. We provide trade advice to complement the prevailing expert consensus on BioDelivery Sciences. Our dynamic recommendation engine uses a multidimensional algorithm to analyze the company's potential to grow using all technical and fundamental data available at the time.
We determine the current worth of BioDelivery Sciences Internatio using both absolute as well as relative valuation methodologies to arrive at its intrinsic value. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of BioDelivery Sciences based exclusively on its fundamental and basic technical indicators. By analyzing BioDelivery Sciences's financials, quarterly and monthly indicators, and related drivers such as dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of BioDelivery Sciences's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of BioDelivery Sciences. We calculate exposure to BioDelivery Sciences's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to BioDelivery Sciences's related companies.

BioDelivery Sciences Investment Alerts

BioDelivery investment alerts and warnings help investors to get more proficient at understanding not only critical technical and fundamental signals but also the significant portfolio-centered indicators. These indicators include beta, alpha, and other risk-related measures that will help you in monitoring BioDelivery Sciences Internatio performance across your portfolios.Please check all investment alerts for BioDelivery

BioDelivery Sciences Valuation Ratios as Compared to Competition

Our valuation model uses many indicators to compare BioDelivery value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across BioDelivery Sciences competition to find correlations between indicators driving the intrinsic value of BioDelivery.

What do experts say?

Stock analysis is a method for investors and traders to make buying and selling decisions. By studying and evaluating past and current data, investors and traders attempt to gain an edge in the markets by making informed decisions. It is good to see analyst projects for BioDelivery Sciences, but it might be worth checking our own buy vs. sell analysis

Sale by Todd Davis of 50000 shares of BioDelivery Sciences

Legal trades by BioDelivery Sciences insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
BioDelivery insider trading alert for sale of common stock by Todd Davis, the corporate stakeholder, on 20th of August 2020. This event was filed by Biodelivery Sciences Inte with SEC on 2020-08-20. Statement of changes in beneficial ownership - SEC Form 4 [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

What is driving BioDelivery Sciences Investor Appetite?

The modest gains experienced by current holders of BioDelivery Sciences could raise concerns from stockholders as the firm closed today at a share price of 4.58 on very low momentum in volume. The company executives have been quite successful in maneuvering the stock at opportune times to take advantage of all market conditions in July. The stock standard deviation of daily returns for 30 days investing horizon is currently 3.48. The above-average risk is mostly attributed to market volatility and speculations regarding some of the upcoming earning calls from BioDelivery Sciences partners.
 2017 2018 2019 2020 (projected)
Revenues USD61.98 M55.64 M111.39 M120.18 M
Revenues61.98 M55.64 M111.39 M120.18 M

Margins Breakdown

BioDelivery profit margins show the degree to which it makes money. Margin indicators are used not only by investors but also by creditors or BioDelivery Sciences itself as indicators of financial health and management effectiveness. Please look more closely at the different varieties of BioDelivery Sciences profit margins.
Operating Margin3.62
EBITDA Margin0.12
Gross Margin0.73
Profit Margin(0.15)


BioDelivery Sciences Earnings Before Interest Taxes and Depreciation Amortization EBITDA is nearly stable at the moment. Also, BioDelivery Sciences Average Assets is increasing over the last 8 years.

Can BioDelivery Sciences build up on the current rise?

Value At Risk just dropped to -4.27, may hint to upcoming price decrease. BioDelivery Sciences Internatio shows above-average downside volatility for the selected time horizon. We advise investors to inspect BioDelivery Sciences Internatio further and ensure that all market timing and asset allocation strategies are consistent with the estimation of BioDelivery Sciences future alpha.

Our Final Takeaway

While other entities under the biotechnology industry are still a bit expensive, BioDelivery Sciences may offer a potential longer-term growth to stockholders. While some stockholders may not share our view we believe that the current risk-reward utility is not appealing enough to do any trading. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to BioDelivery Sciences.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Achuva Shats do not own shares of BioDelivery Sciences Internatio. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com